Mast cell activation disorders (MCAD) encompass a wide range of immune-mediated conditions characterized by episodic or chronic mast cell activation, ...
TipRanks on MSN
Cogent Biosciences’ Phase 2 Study on Bezuclastinib: A Potential Game-Changer for Advanced Systemic Mastocytosis
Cogent Biosciences, Inc. (($COGT)) announced an update on their ongoing clinical study. Cogent Biosciences, Inc. is conducting a Phase 2 clinical ...
Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback